Similarly, studies on hematologic malignancies have demonstrated that REGNASE-1 directly targets TCF7 mRNA, and its deficiency promotes TCF-1 expression, thereby enhancing the persistence of anti-tumor response of CAR-T cells [133]. Here, TCF7 is linked to hematologic disorder.